96 completed, 12 unknown, 10 recruiting, 10 terminated. 140 Phase 2, 15 Phase 1, 15 Phase 3.
Follow Diabetic Nephropathies: new trials by email Literature Review of Diabetic Nephropathies trials Research Report on Diabetic Nephropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Not yet recruiting | University Medical Center Groningen | 36 | 2027-01-01 | 2026-10-20 |
| Mesenchymal Stem Cells for Chronic Kidney Diseases 0.9% sodium chloride, MSCs - Kidney Disease, Chronic, Diabetic Kidney Disease (DKD) | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medical University | 32 | 2026-11-01 | 2026-11-16 |
| Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial Umbilical Cord Mesenchymal Stem Cells - Diabetic Nephropathy Type 2 | Phase 1 / Phase 2 | Recruiting | PT. Prodia Stem Cell Indonesia | 10 | 2026-07-01 | 2026-02-09 |
| Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease ALN-ANG3, Evinacumab, Placebo - Diabetic Kidney Disease (DKD) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 195 | 2026-01-09 | 2026-10-27 |
| Formoterol in Diabetes Formoterol furmarate (20 μg) - Diabetic Nephropathies, Diabetic Kidney Disease | Phase 2 | Recruiting | Medical University of South Carolina | 120 | 2025-12-01 | 2026-02-05 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| Lactoferrin Supplementation in Diabetic Nephropathy Lactoferrin, Antidiabetic, Placebo - Diabetic Nephropathy | Phase 2 | Recruiting | Ain Shams University | 60 | 2025-08-01 | 2026-08-14 |
| P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease 2HPβCD - Diabetic Kidney Disease | Phase 2 | Withdrawn | ZyVersa Therapeutics, Inc. | 2025-06-11 | 2025-11-25 | |
| Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease Amimestrocel - Diabetic Kidney Disease (DKD) | Phase 2 | Recruiting | Chinese PLA General Hospital | 120 | 2025-06-09 | 2026-07-14 |
| Efficacy and Safety Study of Isuzinaxib in Subjects With DKD Isuzinaxib, Placebo - Diabetic Kidney Disease (DKD) | Phase 2 | Recruiting | Aptabio Therapeutics, Inc. | 186 | 2025-05-26 | 2025-07-18 |
| Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies | Phase 2 | Not yet recruiting | Steno Diabetes Center Copenhagen | 69 | 2025-02-01 | 2025-01-27 |
| SGLT2 Adjunct in T1D Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic | Phase 2 / Phase 3 | Completed | Ain Shams University | 86 | 2024-11-20 | 2026-05-18 |
| Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy. Oligo-fucoidan, Fucoxanthin, L-carnitine Formula, Zinc yeast (FFL) - Diabetic Kidney Disease (DKD) | Phase 2 | Completed | Taipei Medical University WanFang Hospital | 63 | 2024-11-06 | 2026-09-04 |
| The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. R3R01, Placebo - Diabetic Kidney Disease | Phase 2 | Recruiting | River 3 Renal Corp. | 60 | 2024-10-10 | 2026-09-23 |
| Clinical Outcome of Vinpocetine in Diabetic Nephropathy Vinpocetine, Standard Therapy, Placebo - Diabetic Kidney Disease, Diabetic Nephropathies | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2024-07-10 | 2024-07-11 |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Walden Biosciences | 96 | 2024-07-02 | 2026-08-03 |
| Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes Placebo, HRS-7535 - Diabetic Kidney Disease, Type 2 Diabetes | Phase 2 | Completed | Shandong Suncadia Medicine Co., Ltd. | 281 | 2024-06-21 | 2026-01-05 |
| Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease Dendritic cell immunotherapy - Diabetic Kidney Disease (DKD) | Phase 1 / Phase 2 | Active not recruiting | PT. JES Kasih Nusantara Sejahterah | 80 | 2024-05-01 | 2025-12-05 |
| Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes Semaglutide, Placebo - Diabetic Kidney Disease, Type 1 Diabetes | Phase 2 | Recruiting | University of Washington | 60 | 2024-04-05 | 2026-06-02 |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD - Chronic Kidney Disease | Phase 2 | Completed | Mineralys Therapeutics Inc. | 60 | 2023-12-14 | 2026-06-03 |
Showing 20 of 140. Sign in to see all of them.
Diabetes Mellitus, Type 2 (31) · Renal Insufficiency, Chronic (26) · Diabetes Mellitus (23) · Kidney Diseases (18) · Proteinuria (14) · Albuminuria (12) · Diabetes Mellitus, Type 1 (11) · Diabetes Complications (7) · Hypertension (7) · Glomerulonephritis, IGA (5) · Endocrine System Diseases (3) · Kidney Failure, Chronic (3) · Urologic Diseases (3) · Glomerulonephritis (2)
Female Urogenital Diseases (140) · Female Urogenital Diseases and Pregnancy Complications (140) · Male Urogenital Diseases (140) · Urogenital Diseases (140) · Endocrine System Diseases (137) · Urologic Diseases (137) · Diabetes Complications (133) · Kidney Diseases (122) · Diabetes Mellitus (117) · Nutritional and Metabolic Diseases (58) · Glucose Metabolism Disorders (56) · Metabolic Diseases (56) · Pathological Conditions, Signs and Symptoms (47) · Pathologic Processes (30) · Disease Attributes (29)
Atrasentan (6) · dapagliflozin (5) · empagliflozin (4) · Acetylcysteine (3) · Hypoglycemic Agents (3) · Spironolactone (3) · Standard of Care (3) · bardoxolone methyl (3) · finerenone (3) · p-Aminohippuric Acid (3) · pyridoxamine dihydrochloride (3) · semaglutide (3) · CCX140-B (2) · Cholecalciferol (2) · Colchicine (2)
Tanabe Pharma Corporation (6) · University of Colorado, Denver (5) · AbbVie (prior sponsor, Abbott) (4) · Ain Shams University (4) · AstraZeneca (4) · Bayer (4) · University of Washington (4) · Biogen (3) · Eli Lilly and Company (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · Shiraz University of Medical Sciences (3) · Amgen (2) · Aptabio Therapeutics, Inc. (2) · BioStratum (2)
United States (60) · Canada (18) · Japan (17) · Australia (15) · Denmark (15) · Germany (12) · Italy (12) · United Kingdom (12) · South Korea (11) · Spain (11) · Hungary (10) · Poland (10) · Netherlands (9) · China (8) · Czechia (8)
Petter Bjornstad, MD (3) · Blai Coll, MD (2) · Connie L Davis, MD (2) · Hiddo J Lambers Heerspink, PhD, PharmD (2) · Jamshid Roozbeh, MD (2) · Masaomi Nangaku, Professor (2) · Paolo Fanti, MD (2) · Thorsten P Degenhardt, Ph.D. (2)
PMID 33107592, PMID 41805697, PMID 28756065, PMID 37916745, PMID 23986513, PMID 31583611, PMID 32974732, PMID 38537621, PMID 11238785, PMID 11304102, PMID 11565517, PMID 11565518, PMID 11832527, PMID 12684357, PMID 15273542, PMID 15380496, PMID 15632335, PMID 16120818, PMID 16188903, PMID 18430778, PMID 18435772, PMID 18525041, PMID 18701613, PMID 19420913, PMID 19808241, PMID 19954692, PMID 20150934, PMID 20693353, PMID 20700413, PMID 20876408, PMID 21055801, PMID 21270268, PMID 21602457, PMID 21693741, PMID 21699484, PMID 21931075, PMID 22187472, PMID 22461535, PMID 22723580, PMID 22770926, PMID 23288372, PMID 23333585, PMID 23362314, PMID 23787544, PMID 23804455, PMID 24149519, PMID 24356416, PMID 24622263, PMID 24722445, PMID 25352176
2016 (2), 2018 (2), R21AT004490 (2), 1KL2RR025015-01 (1), 2004 (1), 2005 (1), 2014 (1), 2017 (1), 2019 (1), I01CX000264 (1), P30DK017047 (1), R01DK063017 (1), R21AT002367 (1)